Take orally, 15-30 minutes before meals. Shake the bottle well before each use. Measure the dose accurately using the provided measuring spoon or cup.

Domperidone acts as a peripheral dopamine D2 receptor antagonist. It blocks dopamine receptors in the chemoreceptor trigger zone (CTZ) in the brain, thereby inhibiting nausea and vomiting. It also blocks peripheral dopamine receptors in the gastrointestinal wall, which leads to increased gastric motility and faster gastric emptying without affecting gastric secretions.

• •Hypersensitivity to Domperidone or any component of the suspension.
• •Patients with known prolongation of cardiac conduction intervals, particularly QTc.
• •Patients with significant underlying cardiac diseases (e.g., congestive heart failure).
• •Patients with hepatic impairment (moderate to severe).
• •Patients with pituitary tumor (prolactinoma).
• •Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin).
• •Concomitant use with QTc-prolonging drugs.
• •Patients with gastrointestinal hemorrhage, mechanical obstruction, or perforation.

Store in a cool, dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions (e.g., involuntary muscle movements, dystonia), and convulsions. Treatment is symptomatic and supportive, including gastric lavage or activated charcoal. Anticholinergic, anti-Parkinsonian drugs may be useful for extrapyramidal reactions.

Pregnancy Category C: Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Lactation: Domperidone is excreted in breast milk in small amounts. Breastfeeding is generally not recommended if Domperidone use is essential.